PRC
SRPT icon

Pearl River Capital’s Sarepta Therapeutics SRPT Stock Holding History

Pearl River Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,196
Closed -$932K – 612
2024
Q1 		$932K Buy
+7,196
New +$881K 0.15% 202
2022
Q3 		– Sell
-9,220
Closed -$691K – 552
2022
Q2 		$691K Buy
9,220
+4,296
+87% +$316K 0.16% 205
2022
Q1 		$385K Sell
4,924
-6,512
-57% -$499K 0.11% 274
2021
Q4 		$1.03M Buy
+11,436
New +$978K 0.28% 114
2020
Q1 		– Sell
-2,614
Closed -$337K – 707
2019
Q4 		$337K Buy
+2,614
New +$264K 0.13% 302
2019
Q2 		– Sell
-1,226
Closed -$146K – 455
2019
Q1 		$146K Buy
1,226
+1,026
+513% +$132K 0.36% 128
2018
Q4 		$22K Buy
+200
New +$25K 0.1% 265

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Pearl River Capital's SRPT Position: Q2 2024 in Review

Pearl River Capital sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 7,196 shares — an estimated $932K sold.

Pearl River Capital first reported a position in SRPT in Q4 2018 and held it in 7 quarters. The position peaked at $1.03M in Q4 2021. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

  • Pearl River Capital reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Pearl River Capital sold 7,196 Sarepta Therapeutics shares in Q2 2024, an estimated $932K.
  • Pearl River Capital first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 7 quarters.
  • Pearl River Capital's Sarepta Therapeutics position peaked at $1.03M in Q4 2021.
  • 483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.